We use our own and third-party cookies to offer our services and collect statistical data. If you continue browsing our site, it is understood that you accept said cookies. More information

Accept
Back

Clinical Trial Monitoring

08-07-2015
Clinical Trial MonitoringClinical Trial Monitoring
Clinical Trial MonitoringClinical Trial Monitoring
Monitoring is key when carrying out any clinical trial. At BioClever,  all clinical trials are monitored using state-of-the-art tools, which facilitate follow-up and allow investigators to associate data from different studies, under the control of the Project Manager, our link with the client, always ready for clarifying any doubts about the design or development of the studies or trials conducted. 
  
Thus, clinical trial monitoring helps control (and sometimes predict), at any time, any issues that may require more time; or, if it involves an unexpected circumstance, it enables us to offer a quick solution to prevent any modifications of the results of the clinical trial that is being conducted and thus allow us to conclude it with the utmost reliability and professionalism that characterize us.

Monitoring our clinical trials to obtain results

At BioClever we have a specific tool to monitor clinical trials that allows anyone involved, whether the investigator, the client or the Project Manager, to control the different phases. This system is Clinsight, an electronic tool that allows us to carry out and automate the whole clinical trial process, thus enabling us to monitor it in a faster, more agile and reliable way, with access to any information that may be required at any time to finish preparing the final report.  

Related news

Regulations concerning clinical trials with drug products
20-11-2016

Regulations concerning clinical trials with drug products

At the 11th Congress held by the Medical Association of the Pharmaceutical Industry (AMIFE, as per the Spanish acronym), held on November 12-14 in Madrid, one of the issues discussed was the status of the Clinical Trial Royal Decree, which is currently awaiting the ruling of the State Council, since the text is almost finished, as stated by Mr. César Hernández, Head of the Committee on Medicinal Products for Human Use of the Spanish Agency of Medicinal Products and Medical Devices (AEMPS).